BioLizard is now an Official Illumina Connected Analytics Implementation Partner
BioLizard has been recognised as an Official Illumina Connected Analytics (ICA) Implementation Partner. With this, BioLizard is recognised as a skilled and competent service partner for ICA users requiring specialised consulting services in data science, bioinformatics, web development and/or systems integration.
Illumina Connected Analytics (ICA) is a secure genomic data platform from Illumina, a global leader in sequencing and array-based technologies, offering hardware and software solutions technologies to produce, access and analyze genomic data. It is an integrated bioinformatics solution providing a cloud-based data platform that enables customers to securely manage, analyse, and explore large volumes of multi-omic data. Through ICA, technical end users like bioinformaticians or software developers can build solutions to process, analyse and gain insights into genomic data.
To support ICA users in the development of specific solutions that require specialized skill sets, official ICA Implementation Partners are technical service providers that have been officially recognised by Illumina to help customers build solutions using ICA. Each partner has been onboarded to ICA to provide either bioinformatics, data science and software development expertise and services.
Illumina has recognised BioLizard as an Official ICA Implementation Partner.
Liesbeth Ceelen, CEO of BioLizard, said: “We are proud to get Illumina’s recognition as a high-quality data science, data management, bioinformatics, and software development service provider. This reflects our company mission to help our customers to fully utilise their scientific data to increase their performance and ability to positively impact billions of lives globally.”
BioLizard is an agile data science, data management and bioinformatics consulting company, providing tailored solutions to the life sciences industry. We specialise in the handling of complex scientific data and the application of state-of-the-art technologies for data-driven R&D, drug development, clinical trials, healthcare, and other applications. Our main areas of expertise are discovery and real-world evidence projects involving (multi-)omics data.
